Illumina Taps Garret Hampton, One of the World’s Leading Clinical Genomics Experts, to Head its Clinical Genomics Unit
January 03 2017 - 09:00AM
Business Wire
Illumina, Inc. (NASDAQ: ILMN), continuing its strategy to bring
the power of genomics into clinical applications, today announced
it has named one of the world’s top clinical genomics experts to
head its clinical genomics unit. Garret Hampton, PhD, will join as
Executive Vice President of Clinical Genomics for the company,
starting January 9, 2017.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170103005421/en/
Garret Hampton (Photo: Business Wire)
“This is a strategically important hire for Illumina,” said
Francis deSouza, President and Chief Executive Officer of Illumina.
“Garret has been on the front lines of oncology and brings deep
expertise in clinical genomics to the leadership team, key to his
new role leading our clinical genomics organization.”
Garret will be responsible for leading the clinical genomics
group, including the reproductive and genetic health and oncology
businesses, regulatory, clinical and medical affairs, CLIA labs,
and the Chief Medical Officer’s organization. He joins Illumina
from Genentech, Inc., where he was Global Head of Oncology
Biomarker Development and Companion Diagnostics, co-led the Roche
Personalized Medicine R&D Initiative and chaired the
Roche/Foundation Medicine Joint R&D Committee. He previously
held scientific and management roles at Celgene Corporation,
Genomics Institute of the Novartis Research Foundation, and
University of California at San Diego. Garret holds a BA in natural
sciences and genetics and MA in natural sciences from Trinity
College in Dublin, Ireland, and a PhD in cancer genetics from
Imperial Cancer Research Fund and the University College
London.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties. Examples of forward-looking statements
include, but are not limited to, statements we make regarding the
expected availability dates for new products and services and FDA
submission dates and intentions for certain products and services.
Important factors that could cause actual results to differ
materially from those in any forward-looking statements include
challenges inherent in developing, manufacturing, and launching new
products and services, and the other factors that are detailed in
our filings with the Securities and Exchange Commission, including
our most recent filings on Forms 10-K and 10-Q, or in information
disclosed in public conference calls, the date and time of which
are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170103005421/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243rchambers@illumina.comorMedia:Eric Endicott,
858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2023 to Mar 2024